Kristy Ainslie, Ph.D., joined the UNC Eshelman School of Pharmacy in 2014 as an associate professor in the Division of Pharmacoengineering and Molecular Pharmaceutics. Prior to that, she spent almost five years as an assistant professor at the Ohio State University’s Division of Pharmaceutics and Pharmaceutical Chemistry.
The research of the Ainslie Lab is centered on immune-targeted therapies for the development of vaccines and treatment of autoimmune and infectious diseases. Ainslie is currently working on host cell-directed therapeutics for treatment of pathogenic infections as well as the formulation of safer vaccines to prevent infection. Also, she is working on antigen specific therapies to treat autoimmune diseases that suppress the immune response specifically, rather than universally suppressing the immune system, like many current therapies.
Ainslie, who has authored more than 30 peer-reviewed publications, received the Controlled Release Society’s Outstanding Oral Drug Delivery Award in 2007 and 2009.
Originally from Michigan, she received her bachelor of science in chemical engineering from Michigan State University and then earned both her master’s and Ph.D. in chemical engineering from Pennsylvania State University. She completed a postdoctoral fellowship at the University of California at San Francisco.